CICC: Maintain the "outperform Industry" rating for CARDIOFLOW-B with a Target Price of 1.5 Hong Kong dollars.

CICC released a Research Report stating that considering CARDIOFLOW-B (02160) actively promoting cost control, the forecast for the net income attributable to the parent for 2025/26 was adjusted from -4.7 million yuan/+0.94 million yuan to -6.48 million yuan/+6.1 million yuan. The firm maintains an outperform rating for the industry and keeps the Target Price of 1.5 HKD based on the DCF model (WACC=11.2% perpetual growth rate=0.5%) unchanged. The firm noted that due to the slowdown in the valve industry, revenue fell short of its expectations; however, since the company's cost control effects are significant and the impairment of joint ventures was reversed, the reduction in losses exceeded expectations. Key viewpoints from CICC.

Sina Hong Kong Stock MarketApr 3 11:25

CICC: Maintains the "Outperform Industry" rating for CARDIOFLOW-B (02160) with a Target Price of 1.5 Hong Kong dollars.

The company reported its performance for 2024: revenue of 0.362 billion yuan, a year-on-year increase of 7.5%; net loss attributable to the parent company of 49.45 million yuan, compared to a net loss of 0.472 billion yuan in the same period of 2023.

Zhitong FinanceApr 3 09:56 · Ratings

CARDIOFLOW-B (02160.HK): In 2024, losses are expected to be reduced beyond expectations, and a turning point for profitability may be approaching.

The reduction in losses in 2024 exceeds our expectations. The company announced its 2024 performance: revenue of 0.362 billion yuan, +7.5% year-on-year; net loss attributable to shareholders of 49.45 million yuan, compared to a net loss of 0.472 billion yuan in the same period of 2023.

China International Capital CorporationApr 3 07:37

CARDIOFLOW-B (02160.HK) subsidiary entered into a property leasing agreement with MICROPORT in Shanghai.

Gelonghui, April 1 - CARDIOFLOW-B (02160.HK) announced that on April 1, 2025, the company's wholly-owned subsidiary Shanghai MICROPORT CARDIOFLOW signed a property lease agreement with Shanghai MICROPORT. Under this agreement, Shanghai MICROPORT CARDIOFLOW agrees to lease the property to Shanghai MICROPORT for research and office purposes, with the lease term from April 1, 2025, to March 31, 2028 (including the first and last days).

Gelonghui FinanceApr 1 22:36

CARDIOFLOW-B (02160) has granted 8.1383 million stock options.

CARDIOFLOW-B (02160) announced that on March 28, 2025, the company has resolved according to the company's...

Zhitong FinanceMar 29 00:17

The president of Heartlink Medical (02160.HK) has changed.

CARDIOFLOW-B (02160.HK) announced that, effective from March 27 (yesterday), Jeffrey R Lindstrom has resigned as the Company's Executive Director, President, and Director and General Manager of Shanghai Micro-Flow Medical; and Zhang Ruinian has been appointed as the Executive Director, President, and Director and General Manager of Shanghai Micro-Flow Medical.

AASTOCKSMar 28 10:35